• Home  
  • Hims, Noom, peptides, Alterome, KRAS, Sanofi: The Readout
Hims, Noom, peptides, Alterome, KRAS, Sanofi: The Readout
- Health

Hims, Noom, peptides, Alterome, KRAS, Sanofi: The Readout

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Want to stay on top

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today’s newsletter has a bit of everything: peptides, China, Congress, and cancer drugs. Biotech in 2026 is never dull.

Hims and Noom take peptides further into mainstream

Hims & Hers and Noom are getting into the synthetic peptide business, bringing treatments marketed for muscle maintenance, intimacy, and longevity to a much larger audience — often with little evidence to support those uses. Both are already offering compounded drugs and eyeing BPC-157 and TB-500, two of six unapproved peptides covered by a new HHS policy easing enforcement against compounding pharmacies, STAT’s Sarah Todd and Katie Palmer write.

STAT+ Exclusive Story





This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Source: www.statnews.com

About Us

Toolq Media Is a Global News Platform Covering the Latest Developments and Breaking Stories from Around The World, Including World News, Business, Finance, Technology, Health, Politics, Science, Entertainment, Sports, and More.

Toolq

Toolq @2026. All Rights Reserved.